Published in
Royal Society of Chemistry, RSC Advances, 58(9), p. 33903-33911, 2019
DOI: 10.1039/c9ra04590b
Links
Tools
Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Data provided by 
Abstract
The possible reasons that caused low response rate and severe side effects of programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy and corresponding strategies.